TFM
ADMA icon

TFC Financial Management’s ADMA Biologics ADMA Stock Holding History

TFC Financial Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10 Sell
1
-2
-67% -$32 ﹤0.01% 991
2025
Q4 		$55 Buy
+3
New +$51 ﹤0.01% 921

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

TFC Financial Management's ADMA Position: Q1 2026 in Review

TFC Financial Management reduced its ADMA Biologics (ADMA) stake by 67% in Q1 2026, selling an estimated $32 and leaving 1 share worth $10. The position accounts for ﹤0.01% of the portfolio, ranked #991.

TFC Financial Management first reported a position in ADMA in Q4 2025 and has held it in 2 quarters since. The position peaked at $55 in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • TFC Financial Management held 1 share of ADMA Biologics worth $10 as of Q1 2026.
  • TFC Financial Management sold 2 ADMA Biologics shares in Q1 2026, an estimated $32.
  • ADMA Biologics made up ﹤0.01% of TFC Financial Management's portfolio in Q1 2026, its #991 holding.
  • TFC Financial Management first reported a position in ADMA Biologics in Q4 2025 and has held it in 2 quarters since.
  • TFC Financial Management's ADMA Biologics position peaked at $55 in Q4 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on TFC Financial Management's 13F filing for Q1 2026, filed 23 Apr 2026.